



1 H-PURINE 2,6 DIONES : STRONG PHOSPHODIESTERASE INHIBITORS

Dr. Sreeja S.¹, Vani V.², Anagha S. Anil³, Akhila A.⁴, Rizwan Bin Nizar⁵, Sapna Sivanthie Suresh Kumar⁶

^{1, 2, 3, 4, 5, 6} Department of Pharmaceutical Chemistry,
Mar Dioscorus College of Pharmacy, Alathara, Thiruvananthapuram
Kerala, India

Abstract

Purine 2,6 diones is a versatile bioisostere having different pharmacological activities. It is a bicyclic, heterocyclic compound producing phosphodiesterase (PDE) inhibitory activity. PDE is an enzyme corresponding to catalyse the secondary messengers in asthma. In this article, we focused different derivatives of Purine 2,6 -diones which are having PDE inhibitory action and may be applied in the treatment of asthma.


Keywords

Purine 2,6 diones, Cyclic GMP, Phosphodiesterase, Xanthine, Anti asthmatic activity

Introduction


PDE are proteinaceous enzymes responsible for decreasing the cAMP and cGMP. By inhibiting, the PDE increases the cAMP and cGMP in the cell and thereby dilating the bronchi. Therefore, it has been used in the treatment of asthma.^{[15][16][20][26]} Purine 2,6 diones are the heterocyclic compound, having N at positions 1, 3, 7 and 9 which directly contributes to various pharmacological actions of the molecule. The nucleus act as mild CNS stimulant, bronchodilator by inhibiting phosphodiesterase enzymes and non-selective adenosine receptor antagonist.

Chemically, it is a xanthine base containing pyrimidine ring fused with imidazole ring. Purines are the basic nucleus of various antiasthmatic drug such as theophylline and aminophylline.^{[1][2]}




Synthesis

N,N dimethyl urea is treated with cyanoacetic acid in presence of nitric acid in alkaline medium. The intermediate so formed undergoes reduction with formic acid and cyclisation to form a complex structure N-(5-amino-1,3- dimethyl -2,6-dioxo-1,3-diazinan-4-yl) formamide. This is then subjected to demethylation through Polonovski reaction and forms 1H - Purine 2,6 dione.













SAR











The structural activity relationship of Purine 2,6 diones is depicted below. Substitution at N1 position can lead to PDE inhibition, adenosine antagonist activity. Substitution at N¹, N² and N³ shows CFTR activation while no CFTR activation is shown for substitution in N⁵. There is complete loss of potency in substitution at N⁵.^[4]



The aromatic ^[6]and heterocyclic^{[2][3][5][6][8][9][10][12][13][16][17][18][19][21][22][23][24][25]} compounds having anti-asthmatic actions can be linked to the N7 position of 1H-Purine 2,6 diones to exhibit the drug action.

Findings

Sl.No.	Code	Derivative	Substitution site	Structure	Smiles Notation
1.	D1	Benzothiophene	N7		<chem>c1cccc2sccc12</chem>
2.	D2	Pyrazine	N7		<chem>c1cnccn1</chem>
3.	D3	7- Azaindole	N7		<chem>c1cccc2[NH]ccc12</chem>
4.	D4	Phenothiazine	N7		<chem>c1ccc2Sc3ccccc3Nc2c1</chem>
5.	D5	Piperidine	N7		<chem>C1CCCCN1</chem>
6.	D6	Benzothiazole	N7		<chem>c1cccc2scnc12</chem>
7.	D7	Isooxazole	N7		<chem>c1ccno1</chem>
8.	D8	Piperidone	N7		<chem>O=C1CCCCN1</chem>
9.	D9	Benzyl indole	N7		<chem>c1c(ccc2NCCc12)Cc1ccccc1</chem>
10.	D10	Benzimidazole	N7		<chem>c1cccc2[NH]cnc12</chem>

11.	D11	Benzofuran	N7		<chem>c1cccc2occc12</chem>
12.	D12	Indole	N7		<chem>c1cccc2[NH]ccc12</chem>
13.	D13	Benzoxazole	N7		<chem>c1cccc2ocnc12</chem>
14.	D14	Benzothiazole	N7		<chem>c1cccc2scnc12</chem>
15.	D15	Pyrrolidine	N7		<chem>C1CCCN1</chem>
16.	D16	Oxazolidinone	N7		<chem>O=C1NCCO1</chem>
17.	D17	Oxopyrrolidine	N7		<chem>O=C1CCCN1</chem>
18.	D18	Phthalazine	N7		<chem>c1cccc2cnnc12</chem>
19.	D19	Phenylacetic acid	N7		<chem>OC(=O)Cc1ccccc1</chem>
20.	D20	Indazole	N7		<chem>c1cccc2N=NCc12</chem>

Future perspectives

From this review, the different heterocyclic and aromatic compounds substituted to the 7th position N of the Purine 2,6 diones^[1] having promising phosphodiesterase inhibitor activity. Compounds such as theophylline^[2], aminophylline^[28] containing the same nucleus have already found to have anti-asthmatic actions. ^{[7][16]} Hence they may be nominated as a good lead in the anti-asthmatic category.

Reference

1. A, Ślusarczyk M, Jakiela B, Plutecka H, Pocięcha K, Świerczek A, Popiół J, Koczurkiewicz-Adamczyk P, Wyska E, Pękała E. Synthesis and in vitro evaluation of anti-inflammatory, antioxidant, and anti-fibrotic effects of new 8-aminopurine-2, 6-dione-based phosphodiesterase inhibitors as promising anti-asthmatic agents. *Bioorganic Chemistry*. 2021 Dec 1;117:105409.
2. Ye J, Mao L, Xie L, Zhang R, Liu Y, Peng L, Yang J, Li Q, Yuan M. Discovery of a Series of Theophylline Derivatives Containing 1, 2, 3-Triazole for Treatment of Non-Small Cell Lung Cancer. *Frontiers in Pharmacology*. 2021 Oct 26;12:753676.
3. Asif M. Pharmacological activities of various phthalazine and phthalazinone derivatives. *Chem. Int*. 2019;5(1):97-108.

4. Singh N, Shreshtha AK, Thakur MS, Patra S. Xanthine scaffold: scope and potential in drug development. *Heliyon*. 2018 Oct 1;4(10):e00829.
5. Cheekavolu C, Muniappan M. In vivo and in vitro anti-inflammatory activity of indazole and its derivatives. *Journal of Clinical and Diagnostic Research: JCDR*. 2016 Sep;10(9):FF01.
6. Lamming ED. Synthesis of N-heterocycles as anti-asthma drugs and compounds with antimycobacterial properties (Doctoral dissertation, UCL (University College London)).
7. Matera MG, Ora J, Cavalli F, Rogliani P, Cazzola M. New avenues for phosphodiesterase inhibitors in asthma. *Journal of Experimental Pharmacology*. 2021 Mar 15;291-302.
8. Connor DT, Cetenko WA, Mullican MD, Sorenson RJ, Unangst PC, Weikert RJ, Adolphson RL, Kennedy JA, Thueson DO. Novel benzothiophene-, benzofuran-, and naphthalenecarboxamidotetrazoles as potential antiallergy agents. *Journal of medicinal chemistry*. 1992 Mar;35(5):958-65.
9. Keri RS, Chand K, Budagumpi S, Somappa SB, Patil SA, Nagaraja BM. An overview of benzo [b] thiophene-based medicinal chemistry. *European journal of medicinal chemistry*. 2017 Sep 29;138:1002-33.
10. El-Miligy MM, Hazzaa AA, El-Messmary H, Nassra RA, El-Hawash SA. New hybrid molecules combining benzothiophene or benzofuran with rhodanine as dual COX-1/2 and 5-LOX inhibitors: Synthesis, biological evaluation and docking study. *Bioorganic chemistry*. 2017 Jun 1;72:102-15.
11. Cortijo J, Pons R, Dasi F, Marin N, Martinez-Losa M, Advenier C, Morcillo EJ. Bronchodilator and anti-inflammatory activities of SCA40: studies in human isolated bronchus, human eosinophils, and in the guinea-pig in vivo. *Naunyn-Schmiedeberg's archives of pharmacology*. 1997 Dec;356:806-14.
12. Esteve C, González J, Gual S, Vidal L, Alzina S, Sentellas S, Jover I, Horrillo R, De Alba J, Miralpeix M, Tarrasón G. Discovery of 7-azaindole derivatives as potent Orai inhibitors showing efficacy in a preclinical model of asthma. *Bioorganic & Medicinal Chemistry Letters*. 2015 Mar 15;25(6):1217-22.
13. Sharma N. 7-Azaindole Analogues as Bioactive Agents and Recent Results. *Mini reviews in medicinal chemistry*. 2019 Jun 1;19(9):727-36.
14. Sadanandam YS, Shetty MM, Rao AB, Rambabu Y. 10H-Phenothiazines: a new class of enzyme inhibitors for inflammatory diseases. *European journal of medicinal chemistry*. 2009 Jan 1;44(1):197-202.
15. Singh P, D'Auteuil C, Dufour M. Potentiation of blood antiasthmatic xanthine levels by tranquilizers in mice. *European Journal of Drug Metabolism and Pharmacokinetics*. 1976 Oct;1:194-201.
16. Berti F, Daffonchio L, Magni F, Omini C, Rossoni G, Subissi A. LG 30435, a new potential antiasthmatic agent. *European Respiratory Journal*. 1989 Oct 1;2(9):868-73.
17. Alodeani EA, Arshad M, Izhari MA. Drug likeness and physicochemical properties evaluation of the alkaloids found in black pepper: piperine, piperidine, piperettine and piperanine. *European Journal of Pharma and medical research*. 2015;2(6):296-301.
18. Abdelshaheed MM, Fawzy IM, El-Subbagh HI, Youssef KM. Piperidine nucleus in the field of drug discovery. *Future Journal of Pharmaceutical Sciences*. 2021 Dec;7:1-1.
17. Sharma PC, Sinhmar A, Sharma A, Rajak H, Pathak DP. Medicinal significance of benzothiazole scaffold: an insight view. *Journal of enzyme inhibition and medicinal chemistry*. 2013 Apr 1;28(2):240-66.
18. Joseph L, George M. Evaluation of in vivo and in vitro anti-inflammatory activity of novel isoxazole series. *European International Journal of Science and Technology*. 2016;5(3):35-42.
19. Zhu J, Mo J, Lin HZ, Chen Y, Sun HP. The recent progress of isoxazole in medicinal chemistry. *Bioorganic & medicinal chemistry*. 2018 Jul 23;26(12):3065-75.
20. Kwon OK, Lee JW, Xuezheng X, Harmalkar DS, Song JG, Park JW, Hwang D, Min JH, Kim JH, Han HK, Jeong HG. DK-1108 exerts anti-inflammatory activity against phorbol 12-myristate 13-acetate-induced inflammation and protective effect against OVA-induced allergic asthma. *Biomedicine & Pharmacotherapy*. 2020 Dec 1;132:110950.
21. Richards ML, Lio SC, Sinha A, Tieu KK, Sircar JC. Novel 2-(substituted phenyl) benzimidazole derivatives with potent activity against IgE, cytokines, and CD23 for the treatment of allergy and asthma. *Journal of medicinal chemistry*. 2004 Dec 16;47(26):6451-4.
22. Kale M, Chavan V. Exploration of the biological potential of benzoxazoles: An overview. *Mini-Reviews in Organic Chemistry*. 2019 Apr 1;16(2):111-26.

23. Keri RS, Patil MR, Patil SA, Budagumpi S. A comprehensive review in current developments of benzothiazole-based molecules in medicinal chemistry. *European Journal of Medicinal Chemistry*. 2015 Jan 7;89:207-51.
24. Appleby KM, Mewis RE, Olaru AM, Green GG, Fairlamb IJ, Duckett SB. Investigating pyridazine and phthalazine exchange in a series of iridium complexes in order to define their role in the catalytic transfer of magnetisation from para-hydrogen. *Chemical Science*. 2015;6(7):3981-93.
24. Denya I, Malan SF, Joubert J. Indazole derivatives and their therapeutic applications: a patent review (2013-2017). *Expert opinion on therapeutic patents*. 2018 Jun 3;28(6):441-53.
26. Ezeamuzie CI, Rao MS, El-Hashim AZ, Philip E, Phillips OA. Anti-allergic, anti-asthmatic and anti-inflammatory effects of an oxazolidinone hydroxamic acid derivative (PH-251)—A novel dual inhibitor of 5-lipoxygenase and mast cell degranulation. *International Immunopharmacology*. 2022 Apr 1;105:108558.
27. Brown AD, Bunnage ME, Glossop PA, Holbrook M, Jones RD, Lane CA, Lewthwaite RA, Mantell S, Perros-Huguet C, Price DA, Webster R. The discovery of indole-derived long acting β 2-adrenoceptor agonists for the treatment of asthma and COPD. *Bioorganic & medicinal chemistry letters*. 2007 Nov 15;17(22):6188-91.
28. Cooney L, Sinha I, Hawcutt D. Aminophylline dosage in asthma exacerbations in children: a systematic review. *PLoS One*. 2016 Aug 2;11(8):e0159965.

